Acquisition - September 30, 2019
Sobi to acquire Dova Pharmaceuticals
Swedish Orphan Biovitrum (Sobi) has announced a definitive agreement to acquire Dova Pharmaceuticals by means of a tender offer. The transaction is valued at up to USD 915 million on a fully diluted basis The consideration consists of an upfront payment of USD 27.50 per share in cash and, one non-tradeable Contingent Value Right (CVR). […]